Reports Q1 revenue $2.45M, consensus $2.64M. As of March 31, 2019, Dermira had cash and investments of $387.8 million and 53.6 million common shares outstanding. Q1 QBREXZA $2.5M vs. $0.3M last year. The company states Q1 “QBREXZA sales were impacted by the company’s launch-related patient financial assistance program designed to broaden patient access, a component of which is being phased out beginning in the second quarter of 2019 as a result of the company having achieved specific objectives for commercial coverage of QBREXZA. ”
https://thefly.com/landingPageNews.php?id=2905113
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.